Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | AGXT | P21549 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | LPO | P22079 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992719 | 0.89 | GABRA1 (0.59) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL7369701 | 0.88 | CYP1A2 (0.70) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL1145638 | 0.86 | CYP1A2 (0.58) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL24188255 | 0.84 | CYP1A2 (0.57) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL1145636 | 0.84 | CYP1A2 (0.57) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL12125567 | 0.81 | TAAR1 (0.59) | CYP1A2TAAR1IDO1AGXTCHRM2 | |
| SCHEMBL2099512 | 0.80 | CHRM2 (0.66) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL723511 | 0.80 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL30080050 | 0.80 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL20738330 | 0.80 | CYP1A2 (0.53) | CYP1A2TAAR1IDO1AGXTCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139281-B1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | UNIV HEIDELBERG (DE) | 2024-05-08 | — | — | EP | disclosed |
| US-20230151054-A1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | Universität Heidelberg (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151054-A1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | Universität Heidelberg (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230151054-A1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | Universität Heidelberg (DE) | 2023-05-18 | — | — | US | disclosed |
| EP-3901135-A1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | Universität Heidelberg (DE) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151054-A1 | SULFUR EXTRUSION FROM DISULFIDES BY CARBENES | TST, CBS, CTH | CYP1A2 1247/4885TAAR1 3595/4885IDO1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.